GLP-1 analog users had an 18% lower risk of COPD exacerbation (hazard ratio 0.82, 95% CI 0.71–0.94, p = 0.003), a 28% reduced risk of pneumonia (HR 0.72, 95% CI 0.61–0.85, p < 0.001), a 34% reduced risk of oxygen dependence (HR 0.66, 95% CI 0.47–0.91, p = 0.010), and a 40% decreased risk of all-cause mortality (HR 0.60, 95% CI 0.47–0.77, p < 0.001) [149]. This evidence concerns the gene GLP1R and chronic obstructive pulmonary disease.